A Novel Dual-Mechanism Small-Molecule Therapeutic for Alzheimer's Disease
Computationally designing a dual-inhibitor for Alzheimer's disease using molecular-modeling software (including Schrödinger Maestro, SwissADME, and pharmacokinetic analysis tools) — engineered to target both symptom alleviation and disease modification across the full disease trajectory, addressing the shortage of late-stage treatments. Synthesizing, confirming, and validating the molecule via NMR, IR, and a C. elegans Alzheimer's model.